Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Rhea-AI Summary

Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis trials. The company aims to demonstrate FXR314's activity matching results from predictive animal models and 3D human models of ulcerative colitis and Crohn's disease. Murphy emphasized the importance of swift trial completion for investors and patients, noting the strong M&A activity in IBD, referencing Lilly's $3.2B acquisition of Morphic following positive Phase 2a results. The presentation webcast is available for viewing on the Jones Trading website.

Positive

• Ongoing Phase 2a trial for FXR314 in ulcerative colitis
• Strong preclinical and human model data supporting FXR314's efficacy
• Potential for demonstrating significant activity in current clinical trial
• Increased M&A activity in the IBD sector, suggesting potential value for ONVO

Negative

• None.

SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798.

“The promise of FXR314 is strong and I encourage investors to review our newest presentation,” said Keith Murphy, Executive Chairman. “As mergers and acquisitions continue to be strong in inflammatory bowel disease, highlighted by the Lilly acquisition of Morphic for $3.2B after strong Phase 2a results, we are encouraged by our progress and our near-term opportunity to show the value of FXR314 in IBD in our own Phase 2a trial. Completing the trial swiftly is important for our investors and for patients, as we expect to demonstrate activity of FXR314 that matches the strong results we’ve seen in a highly predictive preclinical animal model, as well as the strong data demonstrating the impact of FXR314 to relieve disease aspects in our 3d human models of ulcerative colitis and Crohn’s disease.”

About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com.

Forward Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly and the Registration Statement on Form S-1 (File No. 333-278668), as amended. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. 

Contact
CORE IR
pr@coreir.com

Source: Organovo, Inc.

FAQ

What is the main focus of Organovo's presentation at the Jones Trading Healthcare Conference?

Organovo's presentation focused on FXR314, their treatment for inflammatory bowel disease (IBD), highlighting its strong preclinical and human rationale in Phase 2a ulcerative colitis trials.

What are the near-term value catalysts for Organovo (ONVO) mentioned in the press release?

The near-term value catalysts for Organovo include the completion of the Phase 2a trial for FXR314 in ulcerative colitis and the potential demonstration of its activity matching strong preclinical results.

How does the recent M&A activity in the IBD sector affect Organovo's outlook?

The strong M&A activity in the IBD sector, such as Lilly's $3.2B acquisition of Morphic, encourages Organovo's progress and highlights the potential value of their FXR314 treatment in IBD.

What evidence supports the potential efficacy of Organovo's FXR314 for IBD treatment?

FXR314's potential efficacy is supported by strong results from highly predictive preclinical animal models and data demonstrating its impact on relieving disease aspects in 3D human models of ulcerative colitis and Crohn's disease.